|
US3700612A
(en)
|
1971-06-23 |
1972-10-24 |
Tenneco Chem |
Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8422653D0
(en)
|
1984-09-07 |
1984-10-10 |
Technology Licence Co Ltd |
Monoclonal antibodies
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
US5370872A
(en)
|
1991-08-12 |
1994-12-06 |
Swiss Serum And Vaccine Institute Berne |
Escherichia coliO-polysaccharide-protein conjugate vaccine
|
|
AU685047B2
(en)
|
1992-02-11 |
1998-01-15 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Dual carrier immunogenic construct
|
|
DK0671948T3
(da)
|
1992-06-25 |
1997-09-01 |
Smithkline Beecham Biolog |
Vaccinepræparat indeholdende adjuvanser
|
|
DK0616034T3
(da)
|
1993-03-05 |
2005-02-21 |
Wyeth Corp |
Plasmid til fremstilling af CRM-protein og diphtheria toxin
|
|
NZ274376A
(en)
|
1993-09-22 |
1997-11-24 |
Jackson H M Found Military Med |
Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
|
|
AUPM399594A0
(en)
|
1994-02-21 |
1994-03-17 |
Csl Limited |
Antigenic preparation for treatment or prevention of helicobacter infection
|
|
FI102976B1
(fi)
|
1994-02-28 |
1999-03-31 |
Valtion Teknillinen |
Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa
|
|
NZ304715A
(en)
|
1995-03-22 |
1999-07-29 |
Jackson H M Found Military Med |
Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
|
|
US6299881B1
(en)
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
|
US6491919B2
(en)
|
1997-04-01 |
2002-12-10 |
Corixa Corporation |
Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
|
|
NZ338101A
(en)
|
1997-04-01 |
2002-03-28 |
Corixa Corp |
Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
|
|
US6858211B1
(en)
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
|
DE69935606T9
(de)
|
1998-10-16 |
2021-03-11 |
Glaxosmithkline Biologicals S.A. |
Adjuvanzsysteme und impfstoffe
|
|
WO2001078777A2
(en)
|
2000-04-13 |
2001-10-25 |
Mossman, Sally |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
|
WO2001078787A2
(en)
|
2000-04-18 |
2001-10-25 |
Endobiologics, Incorporated |
Lipopolysaccharide-conjugate vaccine for sepsis treatment
|
|
RU2189253C1
(ru)
|
2001-04-09 |
2002-09-20 |
Государственный научный центр прикладной микробиологии |
Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
|
|
US6676958B2
(en)
|
2001-06-19 |
2004-01-13 |
Advanced Bioadjuvants, Llc |
Adjuvant composition for mucosal and injection delivered vaccines
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
KR20090110951A
(ko)
|
2002-03-07 |
2009-10-23 |
아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 |
원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
|
|
AU2003901008A0
(en)
|
2003-03-04 |
2003-03-20 |
Anadis Ltd |
Composition for the treatment and prevention of bacterial infections
|
|
CN1324134C
(zh)
|
2003-12-22 |
2007-07-04 |
南开大学 |
对大肠杆菌o81型的o－抗原特异的核苷酸
|
|
PL1745069T3
(pl)
|
2004-03-30 |
2009-10-30 |
Nsgene As |
Zastosowanie terapeutyczne czynnika wzrostu NSG33
|
|
CA2607595C
(en)
|
2005-05-11 |
2018-11-27 |
Eth Zuerich |
Recombinant n-glycosylated proteins from procaryotic cells
|
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
|
CA2646891A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
JP4791866B2
(ja)
|
2006-03-24 |
2011-10-12 |
国立大学法人秋田大学 |
下痢原性大腸菌感染症の判別に用いられる固相等
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8691730B2
(en)
|
2007-09-14 |
2014-04-08 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
CA2711503A1
(en)
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
HRP20181259T1
(hr)
|
2008-02-20 |
2018-10-05 |
Glaxosmithkline Biologicals S.A. |
Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
|
|
EA024697B1
(ru)
|
2009-04-27 |
2016-10-31 |
Иммурон Лимитед |
Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени
|
|
CN102481312B
(zh)
|
2009-06-05 |
2015-07-15 |
传染性疾病研究院 |
合成的吡喃葡萄糖脂佐剂
|
|
EP2501406B8
(en)
|
2009-11-19 |
2018-01-24 |
GlaxoSmithKline Biologicals S.A. |
Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
|
|
DK2593594T3
(en)
|
2010-07-16 |
2017-12-11 |
Adimab Llc |
ANTIBODY LIBRARIES
|
|
AR084158A1
(es)
|
2010-12-10 |
2013-04-24 |
Merck Sharp & Dohme |
Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
|
|
WO2013034664A1
(en)
|
2011-09-06 |
2013-03-14 |
Glycovaxyn Ag |
Bioconjugate vaccines made in prokaryotic cells
|
|
US9932598B2
(en)
|
2012-08-02 |
2018-04-03 |
The Regents Of The University Of California |
Metabolic engineering of microbial organisms
|
|
SI2885007T1
(sl)
|
2012-08-16 |
2018-12-31 |
Pfizer Inc. |
Postopki in kompozicije glikokonjugacij
|
|
CA2883000A1
(en)
|
2012-09-10 |
2014-03-13 |
Glycovaxyn Ag |
Bioconjugates comprising modified antigens and uses thereof
|
|
CN110423716A
(zh)
|
2012-10-12 |
2019-11-08 |
葛兰素史密丝克莱恩生物有限公司 |
宿主细胞修饰方法
|
|
CA2889767C
(en)
|
2012-11-07 |
2021-09-21 |
Glycovaxyn Ag |
Production of recombinant vaccine in e. coli by enzymatic conjugation
|
|
EP3363806B1
(en)
|
2012-12-20 |
2022-11-16 |
Pfizer Inc. |
Glycoconjugation process
|
|
WO2014102265A1
(en)
|
2012-12-27 |
2014-07-03 |
Glycovaxyn Ag |
Methods and compositions relating to crm197
|
|
TR201807924T4
(tr)
|
2013-01-17 |
2018-06-21 |
Arsanis Biosciences Gmbh |
MDR e. koli spesifik antikor.
|
|
RS59500B1
(sr)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech Inc |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
|
|
CN103495161B
(zh)
|
2013-10-08 |
2019-06-18 |
江苏康泰生物医学技术有限公司 |
一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
|
|
SG11201602546RA
(en)
|
2013-10-11 |
2016-04-28 |
Glycovaxyn Ag |
Methods of host cell modification
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
AU2014359277B2
(en)
|
2013-12-04 |
2017-10-26 |
Glaxosmithkline Biologicals S.A. |
Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
|
|
JP6590413B2
(ja)
|
2014-02-06 |
2019-10-16 |
エックスフォー・ファーマシューティカルズ（オーストリア）ゲーエムべーハー |
大腸菌特異的抗体配列
|
|
CN106535927B
(zh)
|
2014-02-24 |
2019-09-20 |
葛兰素史密丝克莱恩生物有限公司 |
新颖多糖及其用途
|
|
DK3131577T3
(da)
|
2014-04-17 |
2020-07-13 |
Glaxosmithkline Biologicals Sa |
Modificerede værtsceller og anvendelser deraf
|
|
CN105695497B
(zh)
|
2014-11-27 |
2019-09-24 |
中国人民解放军军事医学科学院生物工程研究所 |
一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
|
|
LT3240895T
(lt)
|
2014-12-30 |
2022-04-11 |
Glaxosmithkline Biologicals S.A. |
Kompozicijos ir būdai, skirti baltymų glikozilinimui
|
|
TWI715617B
(zh)
|
2015-08-24 |
2021-01-11 |
比利時商葛蘭素史密斯克藍生物品公司 |
對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
|
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
AR109621A1
(es)
|
2016-10-24 |
2018-12-26 |
Janssen Pharmaceuticals Inc |
Formulaciones de vacunas contra glucoconjugados de expec
|
|
GB201711635D0
(en)
|
2017-07-19 |
2017-08-30 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
|
CR20210522A
(es)
*
|
2019-03-18 |
2021-12-17 |
Janssen Pharmaceuticals Inc |
Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
|
|
IL286467B2
(en)
|
2019-03-18 |
2026-02-01 |
Janssen Pharmaceuticals Inc |
Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
|
|
FR3098334B1
(fr)
|
2019-07-05 |
2021-07-23 |
Airbus Operations Sas |
Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
|
|
KR20230164108A
(ko)
*
|
2021-04-01 |
2023-12-01 |
얀센 파마슈티칼즈, 인코포레이티드 |
E. coli O18 생물접합체의 생산
|